Hovione has announced the appointment of Conrad Winters as Director, Drug Product Development. Winters most recently was Senior Director of the Compound Properties Group at Xenon Pharmaceuticals and previously held positions with Merck.
Hovione VP of Corporate Research & Development Thomas Eisele commented, “We are very pleased to welcome Dr. Winters to Hovione. His experience in particle engineering, solubilization, drug product development, scale up, and commercialization will enable us to solve our customers’ most challenging problems.”
Winters responded, “I am delighted to join the strong team at Hovione. Already the recognized world leader in pharmaceutical spray drying, I am looking forward to leading the team in developing complimentary technologies to enable Hovione to offer customers’ integrated solutions for any molecule.”
Hovione offers particle engineering, development, and manufacturing services for inhalation products and also licenses its proprietary TwinCaps dry powder inhaler.
Read the Hovione press release.
